HyalJoint Injection (Sodium Hyaluronate)

Adult dosage

As Sodium Hyaluronate, administer 25 mg once a week for 5 consecutive weeks into the intra-articular space of the knee joint or shoulder joint (shoulder joint cavity, subacromial bursa, or biceps brachii tendon sheath). Adjust the frequency of administration as appropriate based on symptoms. This drug is administered intra-articularly, so it should be performed under strict aseptic procedures.

This drug should not be used in patients with a history of hypersensitivity. As it is administered intra-articularly, avoid use if there is a skin disease or infection at the injection site. Use with caution in patients with liver dysfunction or a history of liver impairment. During administration, serious allergic reactions such as shock may occur, so patients should be closely monitored, and if abnormal symptoms appear, administration should be stopped immediately and appropriate treatment initiated. Hypersensitivity symptoms such as swelling, rash, and itching may occur, so administration should be stopped if these symptoms arise. Temporary pain, swelling, redness, and warmth may occur at the injection site, so caution is required. Symptoms such as nausea, vomiting, fever, and headache may also occur. It is preferable to alleviate inflammation before administering this drug to joints with severe inflammation. After administration, stabilizing the joint area is helpful, and care should be taken to prevent the drug from leaking outside the joint. Caution is advised in patients with rheumatoid arthritis or gout arthritis as inflammation may temporarily worsen. Avoid vigorous exercise or prolonged weight-bearing activities within 48 hours after administration. The safety of concurrent administration with other intra-articular injections has not been confirmed, so it is safer not to combine them. The safety of this drug has not been established for pregnant women or women who may become pregnant, so it should be used with caution only when necessary. Lactating women are advised to avoid breastfeeding as the drug may be transmitted in breast milk. The safety for children has not been established, so it should be administered with caution only when necessary. Elderly patients may have decreased physical function, so care is needed during administration. Maintain aseptic conditions during injection, and it is advisable to administer only up to 5 times if symptoms do not improve. If there is excessive joint fluid, it is recommended to aspirate it before administration. This drug is not intended for intravascular administration or ophthalmic use. Due to its high viscosity, care should be taken regarding the size of the injection needle, and the solution should flow well from the ampoule. To avoid foreign matter contamination when cutting the ampoule, it is better to disinfect first. Caution should be taken as precipitation may occur when mixed with certain disinfectants. It is for single use and should be used immediately after opening, with any remaining drug discarded. It is safer to administer this drug after local anesthesia has been given.

Serious side effects

• Urticaria
• edema (facial, eyelids, etc.)
• shock

Mild side effects

Facial erythema, itching, pain (mainly transient pain after administration), swelling, warmth, severe local pressure sensation, petechiae, nausea, vomiting, fever, headache

This drug should be stored in a sealed container to avoid contact with air, ideally at room temperature between 1 degree and 30 degrees Celsius. Storing this way helps maintain the drug's efficacy and prevents deterioration.

Appearance

A colorless, transparent, viscous solution filled in a glass vial or colorless, transparent plastic vial (part of a pre-filled syringe system) with rubber stoppers at both ends.

Package unit

2.5 mL/1 vial, (2.5 mL/1 vial) X 5EA